A Randomized, Placebo-Controlled Trial of Selenium Supplementation in Patients With Type 2 Diabetes

Abstract

Selenium is an antioxidant trace element. Patients with diabetes are shown to have increased oxidative stress together with decreased selenium concentrations. Whether raising serum selenium will improve blood glucose management in diabetes is largely unknown. In this randomized, double-blind placebo-controlled trial, we assessed the effects of selenium on blood glucose, lipid profile, and oxidative stress in 60 patients with type 2 diabetes. Selenium 200 µg/d or placebo was administered orally for 3 months. Serum concentrations of fasting plasma glucose, glycosylated hemoglobin A1c (HbA1c), insulin, and lipid profile, as well as ferric-reducing ability of plasma and thiobarbituric acid-reactive substances were determined in the fasting state at baseline and after 3 months. Mean (SD) serum selenium at baseline was 42.69 (29.47) µg/L and 47.11 (42.86) µg/L in selenium and placebo groups, respectively. At endpoint, selenium concentration reached to 71.98 (45.08) µg/L in selenium recipients compared with 45.38 (46.45) µg/L in placebo recipients (P<0.01). Between-group comparison showed that fasting plasma glucose, glycosylated hemoglobin A1c, and high-density lipoprotein cholesterol were statistically significantly higher in the selenium recipient arm. Other endpoints changes during the course of trial were not statistically different across the 2 treatment arms. This study suggests that selenium supplementation in patients with type 2 diabetes may be associated with adverse effects on blood glucose homeostasis, even when plasma selenium concentration is raised from deficient status to the optimal concentration of antioxidant activity. Until results of further studies become available, indiscriminate use of selenium supplements in patients with type 2 diabetes warrants caution.

The two faces of reactive oxygen species (ROS) in adipocyte function and dysfunction

“…A recent cross-sectional study showed that even Se intake levels considered as adequate were associated with higher T2D prevalence compared to sub-optimal Se intake in a Chinese population (Wei et al, 2015). Likewise, a trial conducted with T2D patients reported worsened hyperglycemia in those subjects who had received Se in form of daily doses of 200 μg sodium selenite for 3 months compared to the placebo group (Faghihi et al, 2014). Interferences of Se and selenoproteins with the insulin-regulated carbohydrate and lipid metabolism are discussed in detail in a recent review (Steinbrenner, 2013), wherein GPx-1 and SeP are highlighted as mediators of adverse effects of Se regarding insulin sensitivity.…”

Association between dietary polyphenols intake and an oxidative stress biomarker: interest of multiple imputation for handling missing covariates and outcomes

“…The outcome was the TBARS concentration, which has also been recently used as an endpoint in clinical trials of selenium supplementation in patients with Type 2 diabetes [36], of exercise training in hemodialysis patients [37]. The association between catechins and biomarkers of oxidation measured with TBARS has been the focus of interest of many studies, particularly because of the abundance of catechins in the human diet.…”

Вміст Фосфоліпідів У Крові Свиней За Умов Стресу

“…Дослідженням впливу короткострокового психологічного стресу на концентрацію ліпідів у крові людей присвячено немало робіт [2,3], а про передзабійний стрес у тварин у літературі є дуже мало відомостей. Стресовий стан у сільського-сподарських тварин і свиней, зокрема, викликає не тільки економічні втрати, але й погіршення якості продукції [4][5][6].…”

“…Досі залишається невивченою зона ризику набутих хвороб печінки (гепатит, фіброз, цироз) у людей, які мають схильність до раку молочної залози (є фактом, що рак викливається вірусом). Залишається невивченим питання, щодо ймовірності не тільки набути хвороби печінки, а й можливості розвитку раку печінки -гепатоцерулярної карциноми [2]. Захворювання печінки зазвичай має тривалий перебіг, без клінічних симтомів.…”